CancerVax Promotes Steven Ruhl to Vice President of Manufacturing Operations.Business Editors/Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 21, 2003 CancerVax Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CNVX) announced today that Steven Ruhl has been promoted to Vice President of Manufacturing Operations. Mr. Ruhl will continue to oversee day-to-day operations in CancerVax's Los Angeles biologics manufacturing facility, and will also direct related activities including production, logistics, facilities management and technical support. "Steven has enhanced operational efficiency and production quality at our biologics manufacturing facility, and we are pleased to have him as a member of our officer team," said David F. Hale, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CancerVax. "Steven's manufacturing expertise has been extremely valuable in producing our specific active immunotherapy active immunotherapy The administration of substances to evoke a protective immune response in the form of specific antibodies. Cf Passive immunotherapy, Vaccine. product Canvaxin(TM) for our two ongoing Phase 3 clinical trials phase 3 clinical trial Phase 3 study. See Phase study. for the treatment of melanoma, and his extensive experience in the manufacture of monoclonal antibodies will be beneficial as we advance our research with several antibodies for the treatment of solid tumor cancers." Prior to joining CancerVax as Executive Director of Manufacturing in April of 2003, Mr. Ruhl served as Director of Manufacturing Operations for IDEC IDEC Instituto Brasileiro de Defesa do Consumidor (Portugese: Brazilian Consumer Protection Agency) IDEC Information Design & End-User Computing IDEC Interior Design Educators Council, Inc. Pharmaceuticals, where he oversaw the continuous (24/7) production of monoclonal antibodies for commercial and clinical use, acted as manufacturing head during U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) and European Agency for the Evaluation of Medicinal Products (EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. ) inspections and served as a co-leader for the Zevalin(TM) FDA Biologics License Application. Prior to joining IDEC, Mr. Ruhl held the position of Manager of Manufacturing with Xoma Corporation, where he was responsible for production of late phase recombinant therapies and managed the manufacturing of additional products utilizing the Xoma facility. Mr. Ruhl also previously served as Associate Director of Manufacturing with Celtrix Pharmaceuticals, where he led the design of a new facility; oversaw process programming, equipment specifications, engineering and construction; and coordinated the initiation of 24/7 operations. He is a member of the International Society for Pharmaceutical Engineering and received his B.S. in Microbiology and Chemistry from Brigham Young University Brigham Young University, at Provo, Utah; Latter-Day Saints; coeducational; opened as an academy in 1875 and became a university in 1903. It is noted for its law and business schools. . CancerVax is traded on the NASDAQ Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors CNVX. CancerVax cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects Side effects Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; and other risks detailed in CancerVax's Securities and Exchange Commission filings, including CancerVax's Prospectus on Form 424 (b)(4) filed on October 30, 2003, as amended. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CancerVax(R) is a registered trademark of CancerVax Corporation. Canvaxin(TM) is a trademark of CancerVax Corporation. |
|
|||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion